Samsung Cuts U.S. Consumer Electronics Jobs as Headquarters Moves to Texas 
GE Vernova Q2 Revenue Tops Estimates as Earnings Miss, Shares Slide Despite Higher 2026 Outlook 
Alphabet Q2 Earnings Beat Estimates as AI Spending, Google Cloud Growth Fuel Outlook 
Domino’s Weighs Appeal After Australian Court Rules Workers Were Misled on Pay 
ASML Trillion-Dollar Valuation: Can Europe’s AI Chip Giant Reach the Historic Milestone? 
Belimo H1 Sales Surge as AI Data Center Cooling Drives More Than Half of Growth 
SpaceX Q2 Earnings on Aug. 4 Set Stage for Historic Insider Share Unlock 
Australia ASIC Tightens Auditor Oversight After KPMG Leak Scandal 
Morgan Stanley Downgrades Adobe, Workday as AI Transition Raises Growth Concerns 
Chalco Shares Jump as Chinalco Plans Up to $300 Million Stake Increase 
Scandinavian Tobacco Group Sells BREAK and Moro Brands to Japan Tobacco for €176 Million 
Ryanair Warns Summer Airfares May Stay Lower as Quarterly Profit Misses Estimates 
Alaska Air Q3 Outlook Misses Estimates as Higher Fuel Costs Weigh on Profit Forecast 
GM Q2 Earnings Beat Estimates as General Motors Raises 2026 Profit Outlook 
Wistron Opens $700M Texas AI Factory to Build Nvidia Superchips in U.S. 
CHA Biotech Co., Ltd., a biotech firm developing and manufacturing cell therapy-related optical, digital, and medical products, has partnered with CanCure, a US-based immunotherapy biotech firm. They agreed to co-develop natural killer (NK) cell therapy.
CHA Biotech confirmed its collaboration with CanCure on Monday, Jan. 29. According to The Korea Times, the company signed a material transfer agreement to design and produce an anti-MIC antibody treatment.
The NK Cells Therapy
It was explained that the anti-MIC antibody earmarks the MIC antigen (MHC class I polypeptide-related sequence) demonstrated by cancer cells. Moreover, the MIC alludes to a type of protein that plays a crucial part in regulating and controlling the NK cell killing of cancer cells. Once the NK cells identify MICA or MICB emerging from cancerous cells, the faculty to quash cancer cells diminishes.
For its project with CanCure, CHA Biotech plans to review the therapeutic effect and level of effectiveness of the combined MIC-targeted antibodies and allogeneic NK cells. CHA Biotech stated, “CanCure’s anti-MIC antibody can reverse the immune suppression of tumor-shed MIC and enhance the tumor-killing ability of NK cells, allowing NK cells more powerful control of cancer cells.”
CHA Biotech and CanCure’s Agreement
Korea Biomedical Review reported that under the agreement signed by CHA Biotech and CanCure, the South Korean biotech firm will receive a material transfer of antibodies that focuses on MHC class I antigens from the latter. After the clinical plan is finalized, the former will check the therapeutic effects of the antibodies and NK cells in different cancer models.
Lee Jung Hyun, the chief executive officer of CHA Biotech, added, “To expand and strengthen CHA Biotech’s NK cell therapy pipelines, we are pursuing multiple combination strategies with immune checkpoint inhibitors and antibodies. We are planning on increasing the speed and success rate of clinical trials for our NK cell therapy through an open innovation approach with novel biopharmaceuticals and technologies.”
Photo by: CHA Biotech Website
